• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于配对设计中通过非单位相对风险进行等效性检验。

On tests of equivalence via non-unity relative risk for matched-pair design.

作者信息

Tang Nian-Sheng, Tang Man-Lai, Chan Ivan Siu Fung

机构信息

Adult Education College, Yunnan University, No 2, North Road of Cuihu, Kunming 650091, P.R. China.

出版信息

Stat Med. 2003 Apr 30;22(8):1217-33. doi: 10.1002/sim.1213.

DOI:10.1002/sim.1213
PMID:12687652
Abstract

Matched-pair design is often used in clinical trials to increase the efficiency of treatment comparison. We consider the problem of equivalence test with a relative risk endpoint in matched-pair studies with binary outcomes, and develop several score and Wald-type statistics for testing a hypothesis of non-unity relative risk. Examples from an assessment of HIV screening test and a cross-over clinical trial of soft contact lenses are used to illustrate the proposed methods. Through simulations we compare the empirical performance of these tests with the test proposed by Lachenbruch and Lynch. We show that a score test based on a reparameterized multinomial model by Tango performs best in the sense that the test satisfactorily controls the type I error rate and its empirical type I error rates are generally much closer to the prespecified nominal significance level than those of the other tests.

摘要

配对设计常用于临床试验,以提高治疗比较的效率。我们考虑在二元结局的配对研究中使用相对风险终点进行等效性检验的问题,并开发了几种得分和 Wald 型统计量,用于检验相对风险不为 1 的假设。通过评估 HIV 筛查试验和软性隐形眼镜交叉临床试验的实例来说明所提出的方法。通过模拟,我们将这些检验的实证性能与 Lachenbruch 和 Lynch 提出的检验进行比较。我们表明,基于 Tango 重新参数化多项模型的得分检验表现最佳,因为该检验能令人满意地控制 I 型错误率,并且其经验性 I 型错误率通常比其他检验更接近预先指定的名义显著性水平。

相似文献

1
On tests of equivalence via non-unity relative risk for matched-pair design.关于配对设计中通过非单位相对风险进行等效性检验。
Stat Med. 2003 Apr 30;22(8):1217-33. doi: 10.1002/sim.1213.
2
A comparison of methods for the construction of confidence interval for relative risk in stratified matched-pair designs.分层配对设计中相对危险度置信区间构建方法的比较。
Stat Med. 2010 Jan 15;29(1):46-62. doi: 10.1002/sim.3744.
3
Tests for equivalence based on odds ratio for matched-pair design.基于匹配对设计的优势比的等效性检验。
J Biopharm Stat. 2005;15(6):889-901. doi: 10.1080/10543400500265561.
4
Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.在药代动力学相互作用和生物等效性交叉试验中,基于非线性混合效应模型的试验模拟评估。
Stat Med. 2005 May 30;24(10):1509-24. doi: 10.1002/sim.2047.
5
Active-control trials with binary data: a comparison of methods for testing superiority or non-inferiority using the odds ratio.二元数据的活性对照试验:使用比值比检验优效性或非劣效性的方法比较
Stat Med. 2008 Feb 10;27(3):353-70. doi: 10.1002/sim.2975.
6
Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.无安慰剂组的非劣效性试验中检验方法的统计风险问题。
J Biopharm Stat. 2007;17(2):201-13. doi: 10.1080/10543400601177343.
7
Comparing two independent incidence rates using conditional and unconditional exact tests.使用条件检验和无条件精确检验比较两个独立发病率。
Pharm Stat. 2008 Jul-Sep;7(3):195-201. doi: 10.1002/pst.289.
8
Sample size determination for matched-pair equivalence trials using rate ratio.使用率比进行配对等效性试验的样本量确定
Biostatistics. 2007 Jul;8(3):625-31. doi: 10.1093/biostatistics/kxl034. Epub 2006 Oct 27.
9
Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes.应用重对数律控制二分类结局累积Meta分析中的I型错误。
Clin Trials. 2007;4(4):329-40. doi: 10.1177/1740774507081219.
10
Testing the non-unity of rate ratio under inverse sampling.在逆抽样情况下检验率比的非一致性。
Biom J. 2007 Aug;49(4):551-64. doi: 10.1002/bimj.200610337.

引用本文的文献

1
Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.在 VALGENT-2 框架内评估 OncoPredict HPV® SCR 检测的临床性能。
J Med Virol. 2023 Jan;95(1):e28417. doi: 10.1002/jmv.28417.
2
Application of the long axial field-of-view PET/CT with low-dose [F]FDG in melanoma.长轴向视野 PET/CT 联合低剂量 [F]FDG 在黑色素瘤中的应用。
Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1158-1167. doi: 10.1007/s00259-022-06070-7. Epub 2022 Dec 7.
3
Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening.
全自动 NeuMoDx HPV 检测在宫颈癌筛查中的临床验证。
Viruses. 2022 Apr 25;14(5):893. doi: 10.3390/v14050893.
4
New Confidence Intervals for Relative Risk of Two Correlated Proportions.两个相关比例相对风险的新置信区间
Stat Biosci. 2023;15(1):1-30. doi: 10.1007/s12561-022-09345-7. Epub 2022 May 20.
5
Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.乳头瘤病毒 HR-HPV 检测试验在 HPV 感染检测方面具有非劣效临床性能:VALGENT 框架评估。
J Clin Pathol. 2023 Mar;76(3):172-176. doi: 10.1136/jclinpath-2021-207864. Epub 2021 Nov 15.
6
Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program.采用高通量 COR 仪器对 Onclarity 检测进行方法迁移后,对丹麦宫颈癌筛查项目中的 SurePath 筛查样本进行临床验证。
Am J Clin Pathol. 2022 Mar 3;157(3):390-398. doi: 10.1093/ajcp/aqab138.
7
Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load.评估用于严重急性呼吸综合征冠状病毒 2 的唾液采样方法的诊断准确性显示出不同的敏感性和与病毒载量的关联。
J Mol Diagn. 2021 Oct;23(10):1249-1258. doi: 10.1016/j.jmoldx.2021.07.017. Epub 2021 Aug 3.
8
Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.Alinity m HR HPV 检测在 VALGENT-3 框架内的临床和分析评估。
J Clin Microbiol. 2021 May 19;59(6). doi: 10.1128/JCM.00286-21.
9
Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.在VALGENT-3框架内对Hybribio的14种高危型HPV与16/18基因分型检测的临床准确性进行评估与优化。
J Clin Microbiol. 2020 May 26;58(6). doi: 10.1128/JCM.00234-20.
10
Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.BD Onclarity HPV 检测在丹麦宫颈筛查项目中使用 SurePath 筛查样本的临床和分析性能,采用 VALGENT 框架。
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01518-19.